Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
About this item
Full title
Author / Creator
Keunen, Olivier , Johansson, Mikael , Oudin, Anaïs , Sanzey, Morgane , Rahim, Siti A. Abdul , Fack, Fred , Thorsen, Frits , Taxt, Torfinn , Bartos, Michal , Jirik, Radovan , Miletic, Hrvoje , Wang, Jian , Stieber, Daniel , Stuhr, Linda , Moen, Ingrid , Rygh, Cecilie Brekke , Bjerkvig, Rolf , Niclou, Simone P. and Klein, George
Publisher
United States: National Academy of Sciences
Journal title
Language
English
Formats
Publication information
Publisher
United States: National Academy of Sciences
Subjects
More information
Scope and Contents
Contents
Bevacizumab, an antibody against vascular endothelial growth factor (VEGF), is a promising, yet controversial, drug in human glioblastoma treatment (GBM). Its effects on tumor burden, recurrence, and vascular physiology are unclear. We therefore determined the tumor response to bevacizumab at the phenotypic, physiological, and molecular level in a...
Alternative Titles
Full title
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_21321221
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_21321221
Other Identifiers
ISSN
0027-8424,1091-6490
E-ISSN
1091-6490
DOI
10.1073/pnas.1014480108
